Study Confirms SKY92 Test Improves Multiple Myeloma Risk Assessment
A new study published in the British Journal of Haematology confirms that the SKY92 gene expression profiling test significantly enhances risk stratification in multiple myeloma patients, outperforming traditional clinical markers, SkylineDx said.
Risk stratification by SKY92 showed significant differences in survival end points, with SKY92 standard-risk patients having a 3-year PFS and OS of 66% and 92% while SKY92 high-risk patients have a 3-year PFS and OS of 39% and 76% respectively, they said.
'This publication confirms years of scientific work and collaboration,' said Jvalini Dwarkasing, PhD, Chief Scientific Officer at SkylineDx. 'The SKY92 signature brings molecular precision to the clinic, giving physicians a powerful tool to reduce uncertainty in a highly complex disease. It's incredibly rewarding to see its positive impact on real-world patient care'.
Contact:
Exec Edge
Editor@executives-edge.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13-06-2025
- Yahoo
Study Confirms SKY92 Test Improves Multiple Myeloma Risk Assessment
By Daniella Parra A new study published in the British Journal of Haematology confirms that the SKY92 gene expression profiling test significantly enhances risk stratification in multiple myeloma patients, outperforming traditional clinical markers, SkylineDx said. Risk stratification by SKY92 showed significant differences in survival end points, with SKY92 standard-risk patients having a 3-year PFS and OS of 66% and 92% while SKY92 high-risk patients have a 3-year PFS and OS of 39% and 76% respectively, they said. 'This publication confirms years of scientific work and collaboration,' said Jvalini Dwarkasing, PhD, Chief Scientific Officer at SkylineDx. 'The SKY92 signature brings molecular precision to the clinic, giving physicians a powerful tool to reduce uncertainty in a highly complex disease. It's incredibly rewarding to see its positive impact on real-world patient care'. Contact: Exec Edge Editor@
Yahoo
05-06-2025
- Yahoo
Nanox AI Bone Solution Receives CE Mark Certification
By Karen Roman Nano-X Imaging Ltd. (Nasdaq: NNOX) said its AI bone solution HealthOST has received CE mark certification which enables its commercialization across Europe. HealthOST examines CT scans to assess vertebral height loss and bone mineral density and helps identify disease risk, such as osteoporosis, before fractures occur, it stated. 'This CE mark for HealthOST represents a significant expansion of our AI capabilities in Europe,' said Erez Meltzer, Nanox CEO and acting Chairman. 'By integrating seamlessly into routine CT scans, HealthOST helps healthcare providers maximize their existing resources, while identifying patients who might otherwise fall through the cracks of traditional screening methods.' Contact: Exec Edge Editor@
Yahoo
21-05-2025
- Yahoo
Jeito Capital Leads $65M Series A to Advance Innovations in Reproductive Medicine
By Daniella Parra Jeito Capital said it led a $65 million Series A funding round in ReproNovo, a biotech company focused on reproductive medicine and women's health/. ReproNovo is addressing male and female infertility and uterine health advancing in RPN-001, an oral treatment for male infertility linked to low testosterone and RPN-002, a first-in-class oral treatment for adenomyosis and improving outcomes in assisted reproductive technologies. 'As approximately one in six people worldwide will face infertility issues, we are proud to support ReproNovo, whose commitment to advancing novel therapies in reproductive health aligns well with our focus on accelerating cutting-edge technologies and the commercialization of treatments with transformative benefits for patients,' Ksenija Pavletic, Partner and Chief Commercial Officer at Jeito Capital, said. Contact: Editor@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
